Nuclear Theme DD Cross-Validation Report
2026-04-13 09:55 · 23.3 KB
Time: 09:55
Date: 2026-04-13
Data source date: 2026-04-12
Validation method: StockAnalysis.com statistics pages, WebSearch for news/developments
Stock prices as of: 2026-04-10 close (Tokyo)
Summary Table
| Ticker | Company | Issue | Severity | Finding |
|---|---|---|---|---|
| 7013.T | IHI Corp | Financials match | LOW | All metrics confirmed. PE 28.94, fwd PE 28.02, ROE 23.6%, op margin 9.1% all match StockAnalysis. X-energy MOU confirmed Mar 16 2026. |
| 7013.T | IHI Corp | NuScale risk elevated | MEDIUM | NuScale stock down 80% from peak, Q4 2025 disappointing, $507M accounting hit, project timelines pushed to 2033-34. IHI's $20M investment at risk. |
| 6501.T | Hitachi | ROE missing from source | LOW | StockAnalysis shows ROE "n/a" -- likely a reporting lag. PE 26.64, fwd PE 25.37, op margin 11.1% all confirmed. |
| 6501.T | Hitachi | BWRX-300 on track | LOW | Darlington construction proceeding on schedule (started May 2025, grid connection ~2030). SE Asia MOU signed Mar 2026. TVA US application under NRC review. |
| 5631.T | JSW | Negative FCF confirmed | MEDIUM | FCF -19.7B confirmed. PE 35.28, fwd PE 34.31 match. Op margin now 9.18% (report says 8.4%) -- slight improvement. 52-week gain +107%. |
| 5631.T | JSW | Valuation stretched | MEDIUM | EV/EBITDA 22.8x is very expensive for a cyclical industrial with negative FCF. FY2026E guidance: sales +16.7%, OP +7.3%. |
| 6841.T | Yokogawa | All metrics confirmed | LOW | PE 24.82, fwd PE 20.73, ROE 12.2%, op margin 14.6% all match. D/E 0.05 confirmed. Best quality in group. |
| 6841.T | Yokogawa | RR SMR catalyst advancing | LOW | Rolls-Royce SMR received UK regulatory justification Mar 25 2026. GDA Step 3 completing Aug 2026. First concrete possible 2027. Bullish for Yokogawa DPCS revenue. |
| 6504.T | Fuji Electric | All metrics confirmed | LOW | PE 19.62, fwd PE 17.13, ROE 11.8%, op margin 10.3% match. FY2026 OP guidance raised to 128.5B. |
| 7004.T | Kanadevia | Operating margin discrepancy | HIGH | Report says op margin 2.0%, but StockAnalysis shows 4.41% for FY2025. H1 FY2026 posted operating LOSS of -7.8B with net loss of -5.5B. Full-year OP forecast revised DOWN 33.2%. Earnings quality deteriorating. |
| 7004.T | Kanadevia | FCF improved but misleading | MEDIUM | StockAnalysis shows FCF -412M (report said -12.8B). Likely different periods. H1 operating loss suggests full-year FCF will be weak again. |
| 6368.T | Organo | All metrics confirmed | LOW | PE 26.42, fwd PE 24.47, ROE 23.5%, op margin 21.4% match. Revenue +9.7%, NI +34% YoY. |
| 6368.T | Organo | Valuation warning | MEDIUM | 52-week gain +202%. P/B 5.7x, P/S 4.25x are premium. EV/EBITDA 19.1x. Priced for perfection. |
| 6370.T | Kurita Water | All metrics confirmed | LOW | PE 38.22, fwd PE 21.67 match. ROE 6.8%, op margin 13.7% confirmed. Q3 FY2026 OP +22.2% YoY is positive. |
| 6370.T | Kurita Water | Trailing PE still elevated | MEDIUM | 38.2x trailing is expensive. Fwd PE 21.67 reflects earnings growth but still above monitoring trigger of 25x. |
| 6302.T | SHI | All metrics confirmed | LOW | PE 20.46, fwd PE 18.63, ROE 4.7%, op margin 4.8% all match. P/B 0.92 confirmed (below book). |
| 6302.T | SHI | BNCT overseas expansion | LOW | NeuCure BNCT system installing in China's Hainan Medical Tourism Pilot Zone, FY2025 start. Positive for thesis but small revenue. |
| ALL | All | Tariff risk | MEDIUM | US imposed 15% tariff on Japanese imports (reduced from 25%). Steel/aluminum/copper at 50%. Supreme Court struck down IEEPA-based tariffs (6-3). Uncertainty remains for nuclear equipment exports. |
Detailed Findings per Company
7013.T IHI Corporation
Price: 3,303 (Apr 10) | Market Cap: 3.50T | 52w Range: 1,378 - 4,698
| Metric | Report | Current | Delta |
|---|---|---|---|
| PE | 28.94 | 28.94 | -- |
| Forward PE | 28.02 | 28.02 | -- |
| P/B | 5.92 | 5.92 | -- |
| ROE | 23.6% | 23.55% | -- |
| Op Margin | 9.1% | 9.07% | -- |
| D/E | 108% | 108% | -- |
| FCF | +68B | +68.3B | -- |
| Div Yield | 0.6% | 0.61% | -- |
Supply Chain Validation:
- X-energy MOU: CONFIRMED (Mar 16, 2026). Partnership to manufacture nuclear-grade components for Xe-100 HTGR. X-energy has 144-unit, 11 GW commercial pipeline. This is a stronger relationship than initially described -- not just MOU but component manufacturing assessment.
- NuScale: RISK ELEVATED. NuScale stock down ~80% from peak. Q4 2025 results disappointing. $507M accounting hit. Key project timeline pushed from 2030 to 2033-34. However, TVA/Entra1 6 GW framework provides long-term pipeline. IHI's $20M investment is small relative to 3.5T market cap.
- GE Vernova aero JV: No change, confirmed.
Material Changes: Strong turnaround from FY2024 loss (-68.2B) to FY2025 NI of 112.7B. Stock +145% in 52 weeks reflects this recovery. PEG 3.13 suggests growth priced in.
Verdict: MAINTAIN at MEDIUM conviction. NuScale headwinds offset by X-energy progress. Valuation is fair but not cheap after 145% run.
6501.T Hitachi
Price: 4,810 (Apr 10) | Market Cap: 21.64T | 52w Range: 3,008 - 6,039
| Metric | Report | Current | Delta |
|---|---|---|---|
| PE | 26.64 | 26.64 | -- |
| Forward PE | 25.37 | 25.37 | -- |
| P/B | 3.30 | 3.30 | -- |
| ROE | N/A | N/A | -- |
| Op Margin | 11.1% | 11.12% | -- |
| D/E | 16% | 16% | -- |
| FCF | +1,390B | +1,394B | -- |
| Div Yield | 1.0% | 0.96% | -- |
Supply Chain Validation:
- GE Hitachi (GEH) BWRX-300: CONFIRMED and advancing. Darlington construction on schedule (May 2025 start, ~2029 completion, grid 2030). This is the most commercially advanced SMR globally.
- TVA Clinch River: CONFIRMED. NRC accepted and is reviewing construction application.
- Poland OSGE: CONFIRMED. Design development agreement signed Feb 24, 2026.
- SE Asia expansion: CONFIRMED. MOU signed Mar 2026 with GE Vernova.
- Sweden (Vattenfall): NEW. GEH/BWRX-300 is one of two finalists in Vattenfall's nuclear technology partner selection.
- AFRY (Sweden): NEW. Main Services Agreement signed Apr 2026 for BWRX-300 deployment support.
Material Changes: Pipeline expanding faster than expected. Multiple geographies (Canada, US, Poland, SE Asia, Sweden) de-risk single-project dependency. However, nuclear remains a small fraction of 21.6T conglomerate.
Verdict: MAINTAIN at MEDIUM conviction. BWRX-300 momentum is strong but diluted in mega-cap. Consider upgrading if Darlington reaches commissioning on schedule.
5631.T Japan Steel Works
Price: 9,836 (Apr 10) | Market Cap: 724B | 52w Range: 5,022 - 10,620
| Metric | Report | Current | Delta |
|---|---|---|---|
| PE | 35.28 | 35.28 | -- |
| Forward PE | 34.31 | 34.31 | -- |
| P/B | 3.53 | 3.53 | -- |
| ROE | 10.5% | 10.54% | -- |
| Op Margin | 8.4% | 9.18% | +0.8pp |
| D/E | 34% | 34% | -- |
| FCF | -19.7B | -19.7B | -- |
| Div Yield | 0.9% | 0.94% | -- |
Supply Chain Validation:
- BWRX-300 forging supplier: Report says "METI confirmed." Unable to independently verify the specific METI confirmation via web search, but JSW's monopoly on single-piece RPV forgings is well-documented. Only manufacturer globally that can forge cores without welds.
- Westinghouse AP1000: Probable, unchanged.
- Domestic restart forgings: Probable, unchanged.
Material Changes:
- Operating margin improved to 9.18% (report said 8.4%) -- positive trend.
- FY2026E guidance: sales 290B (+16.7% YoY), OP 24.5B (+7.3%).
- EV/EBITDA 22.8x is the most expensive in the group on this metric.
- 28B CAPEX for SMR capacity expansion is driving the negative FCF. This is investment-phase spending, not operational deterioration.
- Steel/aluminum tariffs at 50% could impact if JSW exports forgings to US. Need to monitor.
Verdict: MAINTAIN at HIGH conviction but with caution flag. Monopoly position is real and irreplaceable. Negative FCF is investment-driven. But 35x PE on negative cash flow requires May 2026 earnings to show operating CF inflection. If CF stays negative, reduce per monitoring trigger.
6841.T Yokogawa Electric
Price: 5,637 (Apr 10) | Market Cap: 1.44T | 52w Range: 2,678 - 6,317
| Metric | Report | Current | Delta |
|---|---|---|---|
| PE | 24.82 | 24.82 | -- |
| Forward PE | 20.73 | 20.73 | -- |
| P/B | 2.78 | 2.78 | -- |
| ROE | 12.2% | 12.22% | -- |
| Op Margin | 14.6% | 14.55% | -- |
| D/E | 5% | 5% | -- |
| FCF | +88B | +88.2B | -- |
| Div Yield | 1.1% | 1.14% | -- |
Supply Chain Validation:
- Rolls-Royce SMR DPCS: CONFIRMED and strengthened. Feb 2, 2026 contract covers design, validation, hardware, installation, commissioning. Delivered from UK (Runcorn), Czech Republic, and Netherlands. Yokogawa committed to "considerable investments" in UK nuclear supply chain.
- Rolls-Royce SMR UK progress: MAJOR CATALYST ADVANCING.
- GBE-N obtained Electricity Generation Licence (Mar 11, 2026)
- Rolls-Royce SMR received regulatory justification (Mar 25, 2026) -- first SMR in UK
- GDA Step 3 completing Aug 2026
- First concrete possible 2027, revenue service by 2031
- Czech Republic (CEZ): Up to 3 GW planned
- Sweden (Vattenfall): Final stage selection
- Saudi Aramco, Shell, ADNOC: No changes, all confirmed.
Material Changes: The Rolls-Royce SMR catalyst is materializing faster than expected. UK regulatory approvals in Q1 2026 are significant de-risking events. Yokogawa's DPCS is positioned for multi-geography revenue as RR SMR scales (UK + Czech + potentially Sweden). ROIC of 19.2% is best-in-class.
Verdict: MAINTAIN at HIGH conviction. Consider UPGRADE to top weighting. The RR SMR catalyst is no longer speculative -- regulatory approvals are landing. Quality metrics (ROE, ROIC, near-zero debt, 14.6% margin) are best in the portfolio. Forward PE 20.7x is reasonable for this quality.
6504.T Fuji Electric
Price: 11,395 (Apr 10) | Market Cap: 1.68T | 52w Range: 5,215 - 13,945
| Metric | Report | Current | Delta |
|---|---|---|---|
| PE | 19.62 | 19.62 | -- |
| Forward PE | 17.13 | 17.13 | -- |
| P/B | 2.12 | 2.12 | -- |
| ROE | 11.8% | 11.82% | -- |
| Op Margin | 10.3% | 10.33% | -- |
| D/E | 13% | 13% | -- |
| FCF | +51B | +51.5B | -- |
| Div Yield | 1.6% | 1.60% | -- |
Supply Chain Validation:
- JNFL Rokkasho 300-channel panel: Confirmed via Fuji Electric product pages. Unchanged.
- 95% nuclear radiation monitoring share: Confirmed via Fuji Electric nuclear product pages. Every operating J-reactor is a customer.
- Honda IGBT: Confirmed, unchanged.
- Bosch SiC JV: Confirmed (Dec 2025 agreement).
- Vestas wind IGBT: Confirmed, unchanged.
Material Changes:
- FY2026 OP guidance RAISED to 128.5B -- positive signal.
- Revenue 1,183B (+4.3% YoY), NI 85.3B -- steady growth.
- Dual nuclear + power semiconductor exposure gives balanced risk.
- 52-week gain +114% but forward PE 17.1x is the most attractive valuation in the group.
- Kashiwazaki-Kariwa Unit 6 restart (Feb 2026) = direct revenue for radiation monitoring.
Verdict: MAINTAIN at HIGH conviction. Best risk/reward in the portfolio. Cheapest forward PE (17.1x), dual theme exposure, raised guidance, near-monopoly nuclear position. No changes needed.
7004.T Kanadevia
Price: 1,213 (Apr 10) | Market Cap: 204B | 52w Range: 774 - 1,228
| Metric | Report | Current | Delta |
|---|---|---|---|
| PE | 19.62 | 19.62 | -- |
| Forward PE | 14.09 | 14.09 | -- |
| P/B | 1.09 | 1.09 | -- |
| ROE | 5.8% | 5.81% | -- |
| Op Margin | 2.0% | 4.41% | DISCREPANCY |
| D/E | 88% | 88% | -- |
| FCF | -12.8B | -412M | DISCREPANCY |
| Div Yield | 2.1% | 2.06% | -- |
KEY ISSUES:
1. Operating margin discrepancy: Report states 2.0%, StockAnalysis shows 4.41% for FY2025. The 2.0% may have been a TTM figure at a different point. However, H1 FY2026 (Apr-Sep 2025) posted an OPERATING LOSS of -7.8B and net loss of -5.5B. This is a severe deterioration.
2. FCF discrepancy: Report says -12.8B, StockAnalysis shows -412M for FY2025. Different measurement periods. Neither is encouraging.
3. Guidance slashed: Full-year FY2026 operating income forecast revised DOWN 33.2% to 18B. Reasons: fewer high-margin domestic Environment projects, Infrastructure business profitability decline, cost overruns.
4. Monitoring trigger hit: D/E at 0.88 is approaching the 1.0 cut threshold. FCF remains negative. The trigger says "If D/E exceeds 1.0 or FCF negative 2+ more periods, cut to 5%."
Supply Chain Validation:
- TEPCO Fukushima JV (Toso Mirai): Unable to find 2026 updates on cask shipments. The JV was announced Apr 2024, targeting FY2025 startup. No confirmation of first cask delivery found.
- NAC International (US subsidiary): Confirmed as wholly-owned, operational.
- Deep Isolation: Probable, unchanged.
Material Changes: Earnings quality is deteriorating significantly. H1 operating loss, guidance cut, and approaching D/E threshold are red flags.
Verdict: DOWNGRADE to LOW conviction. Reduce weight to 5%. Multiple monitoring triggers are flashing. H1 operating loss is a material negative. Wait for May 2026 earnings before re-evaluating. The nuclear decommissioning thesis is long-term valid but near-term execution is poor.
6368.T Organo Corporation
Price: 16,195 (Apr 10) | Market Cap: 745B | 52w Range: 5,220 - 18,260
| Metric | Report | Current | Delta |
|---|---|---|---|
| PE | 26.42 | 26.42 | -- |
| Forward PE | 24.47 | 24.47 | -- |
| P/B | 5.70 | 5.70 | -- |
| ROE | 23.5% | 23.46% | -- |
| Op Margin | 21.4% | 21.38% | -- |
| D/E | 24% | 24% | -- |
| FCF | +19B | +18.8B | -- |
| Div Yield | 1.2% | 1.17% | -- |
Supply Chain Validation:
- BWR IFD condensate monopoly: Confirmed via JAIF Nuclear Industrial Directory listing for Organo. IFD technology in all Japanese BWR condensate vessels.
- TSMC Kumamoto (JASM): Confirmed, unchanged.
- Kashiwazaki-Kariwa Unit 6 restart (BWR, Feb 2026): DIRECT REVENUE EVENT. As a BWR restart, this triggers Organo's monopoly IFD business.
Material Changes:
- Revenue +9.7% YoY to 175.3B, NI +34% to 28.2B -- exceptional growth.
- 52-week gain +202% is extreme. Stock near 52-week high (18,260 high vs 16,195 current).
- P/B 5.7x, P/S 4.25x, EV/EBITDA 19.1x are all premium.
- Monitoring trigger: "If P/B expands >7x without earnings support, trim." Currently at 5.7x -- not yet triggered but approaching.
- Earnings are strong enough to justify current valuations (21.4% op margin, 23.5% ROE).
Verdict: MAINTAIN at HIGH conviction but tighten trim discipline. Fundamentals are excellent. BWR restart tailwind is real and confirmed by Kashiwazaki-Kariwa. However, +202% run requires strict valuation monitoring. Trim if P/B > 7x or if earnings growth decelerates.
6370.T Kurita Water Industries
Price: 8,118 (Apr 10) | Market Cap: 888B | 52w Range: 4,041 - 8,882
| Metric | Report | Current | Delta |
|---|---|---|---|
| PE | 38.22 | 38.22 | -- |
| Forward PE | 21.67 | 21.67 | -- |
| P/B | 2.52 | 2.52 | -- |
| ROE | 6.8% | 6.79% | -- |
| Op Margin | 13.7% | 13.69% | -- |
| D/E | 32% | 32% | -- |
| FCF | +25B | +25B | -- |
| Div Yield | 1.4% | 1.38% | -- |
Supply Chain Validation:
- Samsung/SK Hynix Korea: Confirmed, unchanged.
- Japanese nuclear utilities: Probable, unchanged.
- TSMC Japan: Probable, unchanged.
Material Changes:
- Q3 FY2026 results: Sales 314.2B (+1.6% YoY), OP 40.2B (+22.2% YoY) -- strong profit growth despite modest revenue.
- 16 consecutive years of dividend growth -- confirmed.
- Monitoring trigger: "If fwd PE expands >25x without earnings revision, trim to 5%." Current fwd PE 21.67x -- WITHIN BOUNDS.
- PEG ratio 1.02 is the most attractive PEG in the group, suggesting growth-adjusted valuation is reasonable.
- Nuclear water chemistry exposure is real but hard to size as a standalone revenue contributor.
Verdict: MAINTAIN at MEDIUM conviction. Trailing PE 38x looks expensive but forward PE 21.7x and PEG 1.0 suggest earnings are accelerating. Q3 profit growth of +22.2% supports the thesis. Hold but trim if fwd PE crosses 25x.
6302.T Sumitomo Heavy Industries
Price: 5,266 (Apr 10) | Market Cap: 629B | 52w Range: 2,780 - 6,362
| Metric | Report | Current | Delta |
|---|---|---|---|
| PE | 20.46 | 20.46 | -- |
| Forward PE | 18.63 | 18.63 | -- |
| P/B | 0.92 | 0.92 | -- |
| ROE | 4.7% | 4.67% | -- |
| Op Margin | 4.8% | 4.83% | -- |
| D/E | 37% | 37% | -- |
| FCF | +11B | +11.3B | -- |
| Div Yield | 2.8% | 2.75% | -- |
Supply Chain Validation:
- ITER cryocoolers: Confirmed via SHI Cryogenics Group product line. SHI is the world's largest cryocooler manufacturer with 50+ years experience. Specific ITER contract details not independently verified via web search but consistent with known procurement.
- KEK/J-PARC: Confirmed, unchanged.
- GE/Siemens MRI cryocoolers: Probable, unchanged.
- NeuCure BNCT: CONFIRMED expansion. First overseas installation in China's Hainan Medical Tourism Pilot Zone, FY2025 start. This validates the commercialization pathway.
Material Changes:
- P/B 0.92 (below book value) is the cheapest in the group. For a company with confirmed ITER contracts and BNCT commercialization, this is a value anomaly.
- Low margins (4.8%) and ROE (4.7%) from industrial machinery segments continue to dilute the high-quality niche businesses.
- BNCT China expansion is a new positive catalyst since last data update.
Verdict: MAINTAIN at MEDIUM conviction. Value case intact (below book, 2.75% yield). BNCT overseas expansion is positive. ITER/fusion remains long-term optionality. Low quality metrics (ROE, margin) prevent upgrade.
Macro Updates
NRA Reactor Restart Status
- 15 reactors now operating (up from 14 previously). Kashiwazaki-Kariwa Unit 6 (ABWR, 1,356 MW) restarted Feb 9, 2026 -- TEPCO's first restart since Fukushima.
- Kashiwazaki-Kariwa Unit 7 restart delayed to 2029-2030.
- Tokai-2 (JAPC): NRA approved, awaiting local consent through public dialogue sessions. Timeline uncertain.
- Tomari-3 (Hokkaido Electric): NRA approved Jul 2025, governor approved Dec 2025. Restart targeted "as early as possible in 2027" after seawall completion. Motivated by data center power demand.
- NRA eased anti-terrorism deadlines (Apr 2, 2026): Changed 5-year period start to when reactor begins operation, removing a key restart bottleneck.
- To reach 20% nuclear by FY2040, Japan needs ~27-30 reactors running. Currently at 15. Pace needs to roughly double.
7th Strategic Energy Plan
- Finalized Feb 18, 2025. Language shifted from "reducing dependence" to "maximum use of" nuclear energy.
- Nuclear target: ~20% of electricity by FY2040 (up from 8.5% in 2023).
- Renewables: 40-50% by 2040. Fossil fuels: 30-40%.
- Criticism: Plan described as "both unambitious and a fantasy" by Energy Tracker Asia. Achieving 20% requires 27+ reactors, but at current restart pace (~2/year), only ~24 by 2030.
- 60+ year lifetime extensions approved -- confirmed in plan.
SMR / BWRX-300 Developments
- Darlington (Canada): Construction proceeding on schedule. Started May 2025. First unit grid connection ~2030. Four units planned.
- TVA Clinch River (US): NRC accepted and reviewing construction application for first US BWRX-300.
- Poland (OSGE): Design development agreement signed Feb 24, 2026.
- Southeast Asia: GE Vernova + Hitachi MOU signed Mar 2026 to explore deployment.
- Sweden: GEH BWRX-300 is one of two finalists in Vattenfall's technology partner selection.
- Rolls-Royce SMR (UK): Regulatory justification received Mar 25, 2026. GDA completing Aug 2026. First concrete possible 2027.
- NuScale: Struggling. Stock down ~80%. Idaho CFPP terminated. Key project delayed to 2033-34. TVA/Entra1 6 GW framework is long-term positive.
- X-energy: Active. 11 GW pipeline, 144-unit orderbook. IHI partnership for Japanese component manufacturing.
Data Center Power Demand
- Japan data center electricity consumption projected to triple from 19 TWh (2024) to 57-66 TWh by 2034.
- Peak demand: 6.6-7.7 GW by 2034 = 4% of Japan's total peak load.
- Hokkaido Electric explicitly cited data center demand as motivation for Tomari-3 restart.
- $26B+ in hyperscaler investment committed to Japan (AWS, Google, Microsoft, Oracle).
- Nuclear seen as essential baseload to power AI/data center growth alongside renewables.
US Tariff Situation
- 15% reciprocal tariff on most Japanese imports (reduced from initial 25% proposal via US-Japan framework, Jul 2025).
- 50% tariff on steel, aluminum, copper under Section 232 -- could impact JSW nuclear forging exports.
- Supreme Court struck down IEEPA-based tariffs (6-3 ruling) -- may invalidate the 15% reciprocal tariff but enforcement timeline unclear.
- Japan's $550B investment pledge to US includes nuclear energy as strategic sector.
- Net impact on nuclear theme: Mixed. Tariffs could increase cost of Japanese nuclear components exported to US (IHI, JSW), but bilateral nuclear cooperation agreements may provide carve-outs. Domestic plays (Fuji Electric, Organo, Yokogawa) less exposed.
Recommendations
| Ticker | Company | Current Conviction | Recommendation | Rationale |
|---|---|---|---|---|
| 7013.T | IHI Corp | MEDIUM | MAINTAIN | X-energy advancing, NuScale struggling. Balanced risk. Wait for SMR construction milestones. |
| 6501.T | Hitachi | MEDIUM | MAINTAIN | BWRX-300 pipeline expanding across 5+ geographies. Nuclear diluted in mega-cap. On track. |
| 5631.T | JSW | HIGH | MAINTAIN with caution | Monopoly position is irreplaceable. May 2026 earnings must show CF inflection. 35x PE on negative FCF is a risk. |
| 6841.T | Yokogawa | HIGH | MAINTAIN / consider UPGRADE | RR SMR UK regulatory approvals landing. Best quality metrics in portfolio. DPCS revenue catalyst materializing. |
| 6504.T | Fuji Electric | HIGH | MAINTAIN | Best risk/reward. Cheapest forward PE (17.1x), raised guidance, dual theme. No action needed. |
| 7004.T | Kanadevia | MEDIUM | DOWNGRADE to LOW / reduce to 5% | H1 operating loss, guidance cut -33%, D/E approaching 1.0 threshold. Multiple monitoring triggers flashing. |
| 6368.T | Organo | HIGH | MAINTAIN with tight trim discipline | Excellent fundamentals but +202% run. Watch P/B vs 7x threshold. BWR restart tailwind is real. |
| 6370.T | Kurita Water | MEDIUM | MAINTAIN | Fwd PE 21.7x within bounds. PEG 1.0 is attractive. Q3 profit growth strong. Hold. |
| 6302.T | SHI | MEDIUM | MAINTAIN | Below-book value anomaly. BNCT China expansion is positive. Low quality metrics prevent upgrade. |
Portfolio Rebalance Actions (if implemented)
1. Reduce Kanadevia (7004.T) from 10% to 5%. Reallocate 5% to Yokogawa (6841.T) or Fuji Electric (6504.T).
2. Watch list for May 2026 earnings: JSW (CF inflection?), Kanadevia (further deterioration?), all companies (guidance updates).
3. Tariff exposure monitoring: IHI and JSW have US export exposure. Domestic plays (Fuji Electric, Organo, Yokogawa) are more insulated.
4. Next BWR restart events to watch: Tokai-2 (local consent pending), Tomari-3 (2027 target), Kashiwazaki-Kariwa Unit 7 (2029-30). Each is a direct revenue catalyst for Organo and Fuji Electric.
*Validation performed 2026-04-13. All financial metrics sourced from StockAnalysis.com statistics pages (S&P Global Market Intelligence data). News sourced via web search. Next validation recommended after May 2026 earnings season.*